Eculizumab therapy in an adult with plasma exchange-refractory atypical hemolytic uremic syndrome

American Journal of Hematology

Volumn 85, Issue 12, 2010, Pages 976-977

  Prescott, Hallie C ^a   Wu, Haifeng M ^a   Cataland, Spero R ^a   Baiocchi, Robert A ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; ECULIZUMAB; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADULT; CASE REPORT; CLINICAL ASSESSMENT; CREATININE BLOOD LEVEL; DISEASE COURSE; DRUG TOLERABILITY; ENVIRONMENTAL FACTOR; FEMALE; GLOMERULUS CAPILLARY; HEMODIALYSIS; HEMOLYTIC UREMIC SYNDROME; HEREDITY; HUMAN; KIDNEY BIOPSY; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LETTER; MICROANGIOGRAPHY; PLASMAPHERESIS; PRIORITY JOURNAL; THROMBOCYTE COUNT; TREATMENT DURATION;

ANTIBODIES, MONOCLONAL; FEMALE; HEMOLYTIC-UREMIC SYNDROME; HUMANS; MIDDLE AGED; PLASMA EXCHANGE; SALVAGE THERAPY;

EID: 78649513705     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21862     Document Type: Letter

References (4)

1. Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med. 2009; 361: 1676-1687.
2. Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006; 355: 1233-1243.
3. Gruppo RA, Rother RP. Eculizumab for congenital atypical hemolytic-uremic syndrome. N Engl J Med 2009; 360: 544-546.
4. Nurnberger J, Philipp T, Witzke O, et al. Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med 2009; 360: 542-544.